Stockreport

LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks [Seeking Alpha]

LENZ Therapeutics, Inc.  (LENZ) 
PDF Investing Group Leader Follow Summary Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globa [Read more]